Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 358-367 , March 2010

Outcome of Transplantation for Myelofibrosis

  • Karen K. Ballen

      Affiliations

    • Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Karen K Ballen, MD, Division of Hematology/Oncology, Massachusetts General Hospital, 0 Emerson, Suite 118, Boston, Massachusetts, 02114.
    • ,
  • Smriti Shrestha

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Kathleen A. Sobocinski

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Asad Bashey

      Affiliations

    • The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Francisco Cervantes

      Affiliations

    • Hospital Clinic, IDIBAPS, Barcelona, Spain
    • ,
  • Steven M. Devine

      Affiliations

    • The Ohio State University Medical Center, Columbus, Ohio
    • ,
  • Robert Peter Gale

      Affiliations

    • Celgene Corporation, Summit, New Jersey
    • ,
  • Vikas Gupta

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • ,
  • Theresa E. Hahn

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • William J. Hogan

      Affiliations

    • Mayo Clinic Rochester, Rochester, Minnesota
    • ,
  • Nicolaus Kröger

      Affiliations

    • University Hospital Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Mark R. Litzow

      Affiliations

    • Mayo Clinic Rochester, Rochester, Minnesota
    • ,
  • David I. Marks

      Affiliations

    • United Bristol Healthcare, Bristol, United Kingdom
    • ,
  • Richard T. Maziarz

      Affiliations

    • Oregon Health and Science University, Portland, Oregon
    • ,
  • Philip L. McCarthy

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Gary Schiller

      Affiliations

    • University of California at Los Angeles, Los Angeles, California
    • ,
  • Harry C. Schouten

      Affiliations

    • University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Vivek Roy

      Affiliations

    • Mayo Clinic Jacksonville, Jacksonville, Florida
    • ,
  • Peter H. Wiernik

      Affiliations

    • New York Medical College and Montefiore–North Division, Bronx, New York
    • ,
  • Mary M. Horowitz

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Sergio A. Giralt

      Affiliations

    • M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Mukta Arora

      Affiliations

    • University of Minnesota Medical Center, Minneapolis, Minnesota

Received 10 July 2009 ,Accepted 22 October 2009.

References 

  1. Silverstein MN. Myeloproliferative disease. Curr Hematol Oncol. 1988;6:163–184
  2. Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist. 2003;8:225–231
  3. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013–1018
  4. Cervantes F, Pereira A, Esteve J, et al. Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635–640
  5. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684–690
  6. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901
  7. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123–1132
  8. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105:3493–3501
  9. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030–4036
  10. Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer. 2005;103:32–43
  11. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–2541
  12. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78:533–538
  13. Cervantes F. Modern management of myelofibrosis. Br J Haematol. 2005;128:583–592
  14. Verstovsek SPA, Shah NP, et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2007;110:553a;abstract
  15. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831–2838
  16. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35–40
  17. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–3918
  18. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355–365
  19. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115–4119
  20. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690–697
  21. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12:876–884
  22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  23. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–202
  24. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008;14:748–758
  25. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–369
  26. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586–593
  27. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004;33:1005–1009
  28. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807–813
  29. Barosi G, Bacigalupo A. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Curr Opin Hematol. 2006;13:74–78
  30. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93:1514–1522
  31. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497–1503
  32. Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood. 2001;97:2180–2181
  33. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 1993;7:200–206
  34. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226–2233
  35. Kroger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109:1316–1321
  36. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  37. Dey BR, McAfee S, Sackstein R, et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:604–612
  38. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255–2258
  39. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  40. Merup M, Lazarevic V, Nahi H, et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol. 2006;135:367–373
  41. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008;22:474–486
  42. Maziarz RT, Mesa RA, Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is “when?”. Mayo Clin Proc. 2003;78:941–943

 Financial disclosure: See Acknowledgments on page 366.

PII: S1083-8791(09)00496-0

doi: 10.1016/j.bbmt.2009.10.025

Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 358-367 , March 2010

Article Tools

* Image Usage & Resolution